• Publications
  • Influence
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Catheter-based renal denervation causes substantial and sustained blood-pressure reduction, without serious adverse events, in patients with resistant hypertension, in a proof-of-principle trial of therapeutic renal sympathetic denervation.
“Stress” and coronary heart disease: psychosocial risk factors
There is strong and consistent evidence of an independent causal association between depression, social isolation and lack of quality social support and the causes and prognosis of CHD and there is no strong or consistent evidence for a causal link between chronic life events, work‐related stressors, Type A behaviour patterns, hostility, anxiety disorders or panic disorders and CHD.
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
Post hoc analyses reveal several potential confounding factors that may partially explain the unexpected blood pressure responses in both the sham control and RDN groups.
Renal sympathetic-nerve ablation for uncontrolled hypertension.
The renal sympathetic nerves have been identified as a major contributor to the complex pathophysiology of hypertension in both experimental models and in humans and may be modulated by afferent signaling from renal sensory nerves.
Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
Significant changes in blood pressure after RDN persist long term in patients with treatment-resistant hypertension, with good safety, withGood safety.
Translational medicine: the antihypertensive effect of renal denervation.
  • G. Dibona, M. Esler
  • Medicine
    American journal of physiology. Regulatory…
  • 1 February 2010
A proof-of-principle study in patients with hypertension resistant to conventional therapy has demonstrated that the procedure is safe and produces renal denervation with sustained lowering of arterial pressure.
Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study
Renal denervation improves glucose metabolism and insulin sensitivity in addition to a significantly reducing blood pressure, however, this improvement appeared to be unrelated to changes in drug treatment.
Adverse consequences of high sympathetic nervous activity in the failing human heart.
The results suggest that activation of the sympathetic nervous system in patients with heart failure, specifically the cardiac sympathetic nerves, may contribute to the poor prognosis associated with severe heart failure.
Renal denervation in moderate to severe CKD.
A favorable short-term safety profile and beneficial BP effects of catheter-based renal nerve ablation in patients with stage 3-4 CKD and resistant hypertension are suggested.